Humacyte, Inc. (HUMAW) NASDAQ

1.59

+0.0799(+5.29%)

As of June 21 04:00PM

Currency In USD

Humacyte, Inc.

Address

United States of America

Phone

N/A

Website

N/A

Sector

Healthcare

Industry

Biotechnology

Employees

183

First IPO Date

N/A

Key Executives

NameTitlePayYear Born
Dr. Laura E. Niklason M.D., Ph.D.Founder, President, Chief Executive Officer & Director899,2521963
Dr. Shamik J. Parikh M.D.Chief Medical Officer514,7191973
Dr. Heather Ledbetter Prichard Ph.D.Chief Operating Officer647,7831978
Mr. Dale A. SanderChief Financial Officer, Chief Corporate Development Officer & Treasurer704,3331960
Dr. Juliana L. Blum Ph.D.Co-Founder & Executive Advisor0N/A
Mr. William John ScheesseleChief Commercial Officer01972
Ms. Sabrina OsborneExecutive Vice President of Business Strategy & People0N/A
Mr. Harold AltersonSenior Vice President of Quality0N/A
Dr. Yang Cao M.D., Ph.D.Chief Regulatory Officer01966

Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.